Prognostic role of high Bmi-1 expression in Asian and Caucasian patients with solid tumors: A meta-analysis

Biomedicine and Pharmacotherapy

Volumn 68, Issue 8, 2014, Pages 969-977

  Shao, Yingjie ^a   Geng, Yiting ^a   Gu, Wendong ^a   Ning, Zhonghua ^a   Jiang, Jingting ^a   Pei, Honglei ^a  

^a THE THIRD AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

Bmi 1; Cancer; Meta analysis; Prognosis

Indexed keywords

BMI1 PROTEIN; BMI1 PROTEIN, HUMAN; TUMOR MARKER;

ASIAN CONTINENTAL ANCESTRY GROUP; BIOSYNTHESIS; CAUCASIAN; GENE EXPRESSION REGULATION; GENETICS; HUMAN; META ANALYSIS; METABOLISM; NEOPLASM; PROGNOSIS;

ASIAN CONTINENTAL ANCESTRY GROUP; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; POLYCOMB REPRESSIVE COMPLEX 1; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84916239691     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2014.10.017     Document Type: Article

References (56)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Li Z., Cao R., Wang M., Myers M.P., Zhang Y., Xu R.M. Structure of a Bmi-1-Ring1B polycomb group ubiquitin ligase complex. J Biol Chem 2006, 281:20643-20649.
3. Cao R., Tsukada Y., Zhang Y. Role of Bmi-1 and Ring1A in H2A ubiquitylation and Hox gene silencing. Mol Cell 2005, 20:845-854.
4. Guney I., Wu S., Sedivy J.M. Reduced c-Myc signaling triggers telomere-independent senescence by regulating Bmi-1 and p16(INK4a). Proc Natl Acad Sci U S A 2006, 103:3645-3650.
5. Silva J., Garcia J.M., Pena C., Garcia V., Dominguez G., Suarez D., et al. Implication of polycomb members Bmi-1, Mel-18, and Hpc-2 in the regulation of p16INK4a, p14ARF, h-TERT, and c-Myc expression in primary breast carcinomas. Clin Cancer Res 2006, 12:6929-6936.
6. Siddique H.R., Saleem M. Role of BMI1, a stem cell factor, in cancer recurrence and chemoresistance: preclinical and clinical evidences. Stem Cells 2012, 30:372-378.
7. Tong Y.Q., Liu B., Zheng H.Y., He Y.J., Gu J., Li F., et al. Overexpression of BMI-1 is associated with poor prognosis in cervical cancer. Asia Pac J Clin Oncol 2012, 8:e55-e62.
8. Wang Y., Zhe H., Ding Z., Gao P., Zhang N., Li G. Cancer stem cell marker Bmi-1 expression is associated with basal-like phenotype and poor survival in breast cancer. World J Surg 2012, 36:1189-1194.
9. Yoshikawa R., Tsujimura T., Tao L., Kamikonya N., Fujiwara Y. The oncoprotein and stem cell renewal factor BMI1 associates with poor clinical outcome in oesophageal cancer patients undergoing preoperative chemoradiotherapy. BMC Cancer 2012, 12:461.
10. Li D.W., Tang H.M., Fan J.W., Yan D.W., Zhou C.Z., Li S.X., et al. Expression level of Bmi-1 oncoprotein is associated with progression and prognosis in colon cancer. J Cancer Res Clin Oncol 2010, 136:997-1006.
11. Hu J., Liu Y.L., Piao S.L., Yang D.D., Yang Y.M., Cai L. Expression patterns of USP22 and potential targets BMI-1, PTEN, p-AKT in non-small-cell lung cancer. Lung Cancer 2012, 77:593-599.
12. Liu J.H., Song L.B., Zhang X., Guo B.H., Feng Y., Li X.X., et al. Bmi-1 expression predicts prognosis for patients with gastric carcinoma. J Surg Oncol 2008, 97:267-272.
13. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010, 25:603-605.
14. Tierney J.F., Stewart L.A., Ghersi D., Burdett S., Sydes M.R. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007, 8:16.
15. Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21:1539-1558.
16. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
17. Zhang Y., Zhang Y.L., Chen H.M., Pu H.W., Ma W.J., Li X.M., et al. Expression of Bmi-1 and PAI-1 in esophageal squamous cell carcinoma. World J Gastroenterol 2014, 20:5533-5539.
18. Honing J., Pavlov K.V., Meijer C., Smit J.K., Boersma-van Ek W., Karrenbeld A., et al. Loss of CD44 and SOX2 expression is correlated with a poor prognosis in esophageal adenocarcinoma patients. Ann Surg Oncol 2014, [Epub ahead of print (PMID: 24833101)].
19. Choy B., Bandla S., Xia Y., Tan D., Pennathur A., Luketich J.D., et al. Clinicopathologic characteristics of high expression of Bmi-1 in esophageal adenocarcinoma and squamous cell carcinoma. BMC Gastroenterol 2012, 12:146.
20. Ha S.Y., Kim S.H. Co-expression of Bmi1 and EZH2 as an independent poor prognostic factor in esophageal squamous cell carcinoma. Pathol Res Pract 2012, 208:462-469.
21. Lv J., Cao X.F., Ji L., Zhu B., Wang D.D., Tao L., et al. Association of beta-catenin, Wnt1, Smad4, Hoxa9, and Bmi-1 with the prognosis of esophageal squamous cell carcinoma. Med Oncol 2012, 29:151-160.
22. Liu W.L., Guo X.Z., Zhang L.J., Wang J.Y., Zhang G., Guan S., et al. Prognostic relevance of Bmi-1 expression and autoantibodies in esophageal squamous cell carcinoma. BMC Cancer 2010, 10:467.
23. He X.T., Cao X.F., Ji L., Zhu B., Lv J., Wang D.D., et al. Association between Bmi1 and clinicopathological status of esophageal squamous cell carcinoma. World J Gastroenterol 2009, 15:2389-2394.
24. Lu H., Sun H.Z., Li H., Cong M. The clinicopathological significance of Bmi-1 expression in pathogenesis and progression of gastric carcinomas. Asian Pac J Cancer Prev 2012, 13:3437-3441.
25. Lee H., Yoon S.O., Jeong W.Y., Kim H.K., Kim A., Kim B.H. Immunohistochemical analysis of polycomb group protein expression in advanced gastric cancer. Hum Pathol 2012, 43:1704-1710.
26. Yamazaki H., Mori T., Yazawa M., Maeshima A.M., Matsumoto F., Yoshimoto S., et al. Stem cell self-renewal factors Bmi1 and HMGA2 in head and neck squamous cell carcinoma: clues for diagnosis. Lab Invest 2013, 93:1331-1338.
27. Allegra E., Puzzo L., Zuccala V., Trapasso S., Vasquez E., Garozzo A., et al. Nuclear BMI-1 expression in laryngeal carcinoma correlates with lymph node pathological status. World J Surg Oncol 2012, 10:206.
28. Zhang X.Y., Dong Q.G., Huang J.S., Huang A.M., Shi C.L., Jin B., et al. The expression of stem cell-related indicators as a prognostic factor in human lung adenocarcinoma. J Surg Oncol 2010, 102:856-862.
29. Kikuchi J., Kinoshita I., Shimizu Y., Kikuchi E., Konishi J., Oizumi S., et al. Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance. Cancer 2010, 116:3015-3024.
30. Vonlanthen S., Heighway J., Altermatt H.J., Gugger M., Kappeler A., Borner M.M., et al. The bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression. Br J Cancer 2001, 84:1372-1376.
31. Weng M.Y., Li L., Feng S.Y., Hong S.J. Expression of Bmi-1, P16, and CD44v6 in uterine cervical carcinoma and its clinical significance. Cancer Biol Med 2012, 9:48-53.
32. Zhang X., Wang C.X., Zhu C.B., Zhang J., Kan S.F., Du L.T., et al. Overexpression of Bmi-1 in uterine cervical cancer: correlation with clinicopathology and prognosis. Int J Gynecol Cancer 2010, 20:1597-1603.
33. Min L., Dong-Xiang S., Xiao-Tong G., Ting G., Xiao-Dong C. Clinicopathological and prognostic significance of Bmi-1 expression in human cervical cancer. Acta Obstet Gynecol Scand 2011, 90:737-745.
34. Guo B.H., Feng Y., Zhang R., Xu L.H., Li M.Z., Kung H.F., et al. Bmi-1 promotes invasion and metastasis, and its elevated expression is correlated with an advanced stage of breast cancer. Mol Cancer 2011, 10:10.
35. Pietersen A.M., Horlings H.M., Hauptmann M., Langerod A., Ajouaou A., Cornelissen-Steijger P., et al. EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer. Breast Cancer Res 2008, 10:R109.
36. Arnes J.B., Collett K., Akslen L.A. Independent prognostic value of the basal-like phenotype of breast cancer and associations with EGFR and candidate stem cell marker BMI-1. Histopathology 2008, 52:370-380.
37. Choi Y.J., Choi Y.L., Cho E.Y., Shin Y.K., Sung K.W., Hwang Y.K., et al. Expression of Bmi-1 protein in tumor tissues is associated with favorable prognosis in breast cancer patients. Breast Cancer Res Treat 2009, 113:83-93.
38. Du J., Li Y., Li J., Zheng J. Polycomb group protein Bmi1 expression in colon cancers predicts the survival. Med Oncol 2010, 27:1273-1276.
39. Lin M.X., Wen Z.F., Feng Z.Y., Li Z.K. [Association of Bmi-1 expression with clinicopathological features and prognosis of colorectal cancer]. Nan Fang Yi Ke Da Xue Xue Bao 2009, 29:1816-1819.
40. Li X., Yang Z., Song W., Zhou L., Li Q., Tao K., et al. Overexpression of Bmi-1 contributes to the invasion and metastasis of hepatocellular carcinoma by increasing the expression of matrix metalloproteinase (MMP)2, MMP-9 and vascular endothelial growth factor via the PTEN/PI3K/Akt pathway. Int J Oncol 2013, 43:793-802.
41. Yonemitsu Y., Imazeki F., Chiba T., Fukai K., Nagai Y., Miyagi S., et al. Distinct expression of polycomb group proteins EZH2 and BMI1 in hepatocellular carcinoma. Hum Pathol 2009, 40:1304-1311.
42. Wang H., Pan K., Zhang H.K., Weng D.S., Zhou J., Li J.J., et al. Increased polycomb-group oncogene Bmi-1 expression correlates with poor prognosis in hepatocellular carcinoma. J Cancer Res Clin Oncol 2008, 134:535-541.
43. Farivar S., Zati Keikha R., Shiari R., Jadali F. Expression of bmi-1 in pediatric brain tumors as a new independent prognostic marker of patient survival. Biomed Res Int 2013, 2013:1925-1948.
44. Cenci T., Martini M., Montano N., D'Alessandris Q.G., Falchetti M.L., Annibali D., et al. Prognostic relevance of c-Myc and BMI1 expression in patients with glioblastoma. Am J Clin Pathol 2012, 138:390-396.
45. Song W., Tao K., Li H., Jin C., Song Z., Li J., et al. Bmi-1 is related to proliferation, survival and poor prognosis in pancreatic cancer. Cancer Sci 2010, 101:1754-1760.
46. Yang G.F., He W.P., Cai M.Y., He L.R., Luo J.H., Deng H.X., et al. Intensive expression of Bmi-1 is a new independent predictor of poor outcome in patients with ovarian carcinoma. BMC Cancer 2010, 10:133.
47. Qin Z.K., Yang J.A., Ye Y.L., Zhang X., Xu L.H., Zhou F.J., et al. Expression of Bmi-1 is a prognostic marker in bladder cancer. BMC Cancer 2009, 9:61.
48. Bachmann I.M., Puntervoll H.E., Otte A.P., Akslen L.A. Loss of BMI-1 expression is associated with clinical progress of malignant melanoma. Mod Pathol 2008, 21:583-590.
49. Song L.B., Zeng M.S., Liao W.T., Zhang L., Mo H.Y., Liu W.L., et al. Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells. Cancer Res 2006, 66:6225-6232.
50. Jacobs J.J., Scheijen B., Voncken J.W., Kieboom K., Berns A., van Lohuizen M. Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF. Genes Dev 1999, 13:2678-2690.
51. Jacobs J.J., Kieboom K., Marino S., DePinho R.A., van Lohuizen M. The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 1999, 397:164-168.
52. Lessard J., Sauvageau G. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 2003, 423:255-260.
53. Park I.K., Qian D., Kiel M., Becker M.W., Pihalja M., Weissman I.L., et al. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 2003, 423:302-305.
54. Park I.K., Morrison S.J., Clarke M.F. Bmi1, stem cells, and senescence regulation. J Clin Invest 2004, 113:175-179.
55. Song L.B., Li J., Liao W.T., Feng Y., Yu C.P., Hu L.J., et al. The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells. J Clin Invest 2009, 119:3626-3636.
56. Wu K.J. Direct activation of Bmi1 by Twist1: implications in cancer stemness, epithelial-mesenchymal transition, and clinical significance. Chang Gung Med J 2011, 34:229-238.